ANI Historical Balance Sheet

ANIP Stock

USD 66.33 0.35 0.53%

Trend analysis of ANI Pharmaceuticals balance sheet accounts such as Other Current Liab of 138.7 M, Total Current Liabilities of 203.4 M or Total Stockholder Equity of 450 M provides information on ANI Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of ANI Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using ANI Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ANI Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ANI Pharmaceuticals is a good buy for the upcoming year.

ANI Pharmaceuticals Inventory

143.62 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

About ANI Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ANI Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. ANI Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ANI Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ANI currently owns. An asset can also be divided into two categories, current and non-current.

ANI Pharmaceuticals Balance Sheet Chart

At this time, ANI Pharmaceuticals' Cash is relatively stable compared to the past year. As of 03/27/2025, Non Current Assets Total is likely to grow to about 793.8 M, while Common Stock is likely to drop 1,710.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of ANI Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ANI Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ANI Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ANI Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from ANI Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' Cash is relatively stable compared to the past year. As of 03/27/2025, Non Current Assets Total is likely to grow to about 793.8 M, while Common Stock is likely to drop 1,710.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	65.5M	99.8M	132.1M	138.7M
Total Assets	760.1M	904.4M	1.3B	1.3B

Other Current Liab Total Assets

ANI Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Short Term Investments	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables
Total Assets		0.97	0.9	0.96	0.91	0.7	0.0	0.97	0.58	0.98	0.6	-0.42	0.92	0.57	0.99	0.97	0.96	-0.42	0.97	0.78	-0.22	0.17	0.69	0.81	0.95	0.98
Other Current Liab	0.97		0.92	0.93	0.88	0.63	-0.07	0.98	0.56	0.95	0.57	-0.35	0.86	0.6	0.97	0.96	0.95	-0.35	0.93	0.7	-0.25	0.24	0.63	0.8	0.92	0.97
Total Current Liabilities	0.9	0.92		0.86	0.89	0.68	0.02	0.88	0.44	0.9	0.46	-0.36	0.82	0.51	0.9	0.91	0.84	-0.36	0.85	0.7	-0.12	0.27	0.5	0.68	0.8	0.9
Total Stockholder Equity	0.96	0.93	0.86		0.91	0.69	0.07	0.93	0.64	0.92	0.65	-0.47	0.94	0.6	0.91	0.95	0.97	-0.47	0.99	0.86	-0.17	0.17	0.68	0.77	0.85	0.95
Property Plant And Equipment Net	0.91	0.88	0.89	0.91		0.84	0.15	0.87	0.36	0.92	0.37	-0.47	0.84	0.52	0.88	0.95	0.83	-0.47	0.89	0.85	-0.28	0.33	0.39	0.54	0.8	0.92
Net Debt	0.7	0.63	0.68	0.69	0.84		0.24	0.62	-0.08	0.78	-0.07	-0.47	0.67	0.38	0.68	0.76	0.53	-0.47	0.67	0.77	-0.28	0.3	0.29	0.28	0.61	0.75
Retained Earnings	0.0	-0.07	0.02	0.07	0.15	0.24		-0.15	-0.06	0.04	-0.07	-0.86	0.2	-0.1	-0.03	-0.03	-0.05	-0.86	0.08	0.26	0.41	0.27	0.01	-0.01	-0.13	-0.04
Accounts Payable	0.97	0.98	0.88	0.93	0.87	0.62	-0.15		0.57	0.93	0.59	-0.3	0.83	0.67	0.96	0.97	0.96	-0.3	0.94	0.72	-0.36	0.25	0.64	0.78	0.93	0.98
Cash	0.58	0.56	0.44	0.64	0.36	-0.08	-0.06	0.57		0.43	1.0	-0.2	0.62	0.29	0.53	0.48	0.75	-0.2	0.63	0.4	0.14	-0.13	0.64	0.72	0.5	0.48
Non Current Assets Total	0.98	0.95	0.9	0.92	0.92	0.78	0.04	0.93	0.43		0.45	-0.43	0.88	0.51	0.99	0.96	0.89	-0.43	0.92	0.76	-0.23	0.19	0.62	0.74	0.95	0.97
Cash And Short Term Investments	0.6	0.57	0.46	0.65	0.37	-0.07	-0.07	0.59	1.0	0.45		-0.21	0.63	0.3	0.55	0.5	0.77	-0.21	0.65	0.4	0.13	-0.12	0.65	0.73	0.52	0.49
Common Stock Total Equity	-0.42	-0.35	-0.36	-0.47	-0.47	-0.47	-0.86	-0.3	-0.2	-0.43	-0.21		-0.55	-0.36	-0.38	-0.4	-0.39	1.0	-0.52	-0.59	-0.2	-0.32	-0.38	-0.38	-0.31	-0.4
Common Stock Shares Outstanding	0.92	0.86	0.82	0.94	0.84	0.67	0.2	0.83	0.62	0.88	0.63	-0.55		0.53	0.87	0.86	0.91	-0.55	0.94	0.84	0.04	-0.02	0.76	0.78	0.81	0.88
Other Current Assets	0.57	0.6	0.51	0.6	0.52	0.38	-0.1	0.67	0.29	0.51	0.3	-0.36	0.53		0.53	0.64	0.61	-0.36	0.67	0.6	-0.42	0.08	0.43	0.56	0.58	0.64
Total Liab	0.99	0.97	0.9	0.91	0.88	0.68	-0.03	0.96	0.53	0.99	0.55	-0.38	0.87	0.53		0.95	0.93	-0.38	0.92	0.71	-0.24	0.17	0.68	0.8	0.97	0.97
Property Plant And Equipment Gross	0.97	0.96	0.91	0.95	0.95	0.76	-0.03	0.97	0.48	0.96	0.5	-0.4	0.86	0.64	0.95		0.93	-0.4	0.95	0.81	-0.34	0.3	0.55	0.69	0.91	0.99
Total Current Assets	0.96	0.95	0.84	0.97	0.83	0.53	-0.05	0.96	0.75	0.89	0.77	-0.39	0.91	0.61	0.93	0.93		-0.39	0.97	0.76	-0.19	0.14	0.74	0.84	0.89	0.94
Common Stock	-0.42	-0.35	-0.36	-0.47	-0.47	-0.47	-0.86	-0.3	-0.2	-0.43	-0.21	1.0	-0.55	-0.36	-0.38	-0.4	-0.39		-0.52	-0.59	-0.2	-0.32	-0.38	-0.38	-0.31	-0.4
Other Stockholder Equity	0.97	0.93	0.85	0.99	0.89	0.67	0.08	0.94	0.63	0.92	0.65	-0.52	0.94	0.67	0.92	0.95	0.97	-0.52		0.86	-0.19	0.16	0.71	0.8	0.88	0.95
Short Long Term Debt Total	0.78	0.7	0.7	0.86	0.85	0.77	0.26	0.72	0.4	0.76	0.4	-0.59	0.84	0.6	0.71	0.81	0.76	-0.59	0.86		-0.18	0.17	0.48	0.53	0.65	0.78
Short Term Debt	-0.22	-0.25	-0.12	-0.17	-0.28	-0.28	0.41	-0.36	0.14	-0.23	0.13	-0.2	0.04	-0.42	-0.24	-0.34	-0.19	-0.2	-0.19	-0.18		-0.33	0.11	-0.06	-0.33	-0.33
Short Term Investments	0.17	0.24	0.27	0.17	0.33	0.3	0.27	0.25	-0.13	0.19	-0.12	-0.32	-0.02	0.08	0.17	0.3	0.14	-0.32	0.16	0.17	-0.33		-0.17	-0.08	0.07	0.26
Current Deferred Revenue	0.69	0.63	0.5	0.68	0.39	0.29	0.01	0.64	0.64	0.62	0.65	-0.38	0.76	0.43	0.68	0.55	0.74	-0.38	0.71	0.48	0.11	-0.17		0.84	0.68	0.65
Non Currrent Assets Other	0.81	0.8	0.68	0.77	0.54	0.28	-0.01	0.78	0.72	0.74	0.73	-0.38	0.78	0.56	0.8	0.69	0.84	-0.38	0.8	0.53	-0.06	-0.08	0.84		0.8	0.75
Non Current Liabilities Total	0.95	0.92	0.8	0.85	0.8	0.61	-0.13	0.93	0.5	0.95	0.52	-0.31	0.81	0.58	0.97	0.91	0.89	-0.31	0.88	0.65	-0.33	0.07	0.68	0.8		0.93
Net Receivables	0.98	0.97	0.9	0.95	0.92	0.75	-0.04	0.98	0.48	0.97	0.49	-0.4	0.88	0.64	0.97	0.99	0.94	-0.4	0.95	0.78	-0.33	0.26	0.65	0.75	0.93

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	461.2M	771.6M	760.1M	904.4M	1.3B	1.3B
Other Current Liab	50.1M	60.0M	65.5M	99.8M	132.1M	138.7M
Total Current Liabilities	78.6M	87.5M	99.4M	145.5M	193.7M	203.4M
Total Stockholder Equity	195.7M	358.7M	338.5M	457.6M	428.5M	450.0M
Property Plant And Equipment Net	41.3M	52.7M	43.2M	44.6M	56.9M	59.7M
Net Debt	177.8M	187.1M	238.3M	64.5M	170.1M	178.6M
Retained Earnings	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(100.3M)	(95.3M)
Accounts Payable	11.3M	23.0M	29.3M	36.7M	45.7M	47.9M
Cash	7.9M	100.3M	48.2M	221.1M	144.9M	152.1M
Non Current Assets Total	290.9M	449.8M	415.8M	384.6M	756.0M	793.8M
Cash And Short Term Investments	7.9M	100.3M	48.2M	221.1M	151.2M	158.7M
Common Stock Shares Outstanding	12.0M	12.6M	16.3M	18.2M	19.3M	20.3M
Liabilities And Stockholders Equity	461.2M	771.6M	760.1M	904.4M	1.3B	1.3B
Other Current Assets	5.9M	11.3M	25.2M	25.4M	18.0M	18.9M
Total Liab	265.5M	412.9M	421.5M	446.8M	855.2M	897.9M
Property Plant And Equipment Gross	41.3M	75.6M	76.0M	77.5M	101.7M	106.8M
Total Current Assets	170.3M	321.8M	344.3M	519.8M	527.7M	554.1M
Other Stockholder Equity	212.1M	384.7M	398.8M	504.0M	498.6M	523.5M
Accumulated Other Comprehensive Income	(11.4M)	(3.1M)	12.2M	8.9M	5.3M	5.6M
Short Long Term Debt Total	185.7M	287.4M	286.5M	285.7M	315.0M	160.6M
Short Term Debt	115.7M	9.9M	13.2M	850K	9.2M	8.7M
Current Deferred Revenue	451K	80K	87K	32.5M	37.4M	39.2M
Non Currrent Assets Other	802K	2.2M	2.6M	12.1M	12.2M	12.8M
Non Current Liabilities Total	186.9M	325.3M	322.1M	301.3M	661.5M	694.6M
Net Receivables	95.8M	128.5M	165.4M	162.1M	221.7M	232.8M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	172.4M	286.5M	285.7M	284.8M	614.9M	645.7M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	60.8M	81.7M	105.4M	111.2M	136.8M	143.6M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	188.5M	294.1M	251.6M	209.0M	541.8M	568.9M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Historical Balance Sheet

ANI Pharmaceuticals Inventory

143.62 Million

About ANI Balance Sheet Analysis

ANI Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

ANI Pharmaceuticals balance sheet Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals balance sheet Accounts

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Total Liab	+ 0.99	Non Current Assets Total
Net Receivables	+ 0.99	Property Plant And Equipment Gross

Common Stock	- 0.86	Retained Earnings
Common Stock Total Equity	- 0.86	Retained Earnings
Short Long Term Debt Total	- 0.59	Common Stock
Short Long Term Debt Total	- 0.59	Common Stock Total Equity
Common Stock	- 0.55	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.55	Common Stock Total Equity